Sign On Opportunity: ASH letter to AAHRPP on IRB amendments

[Christine Lagana Riordan]

Dear HRA Member Organizations,

I hope this email finds you well. On behalf of the American Society of Hematology (ASH), I am writing to request your review and signature on a letter that ASH is writing to the Association for the Accreditation of Human Research Protection Programs (AAHRPP) asking for amendments to its guidelines and resources for Institutional Review Boards (IRBs) seeking accreditation or accreditation renewal. These amendments aim to help IRBs work with investigators to increase representation in the selection of research participants. Thus, upholding the justice principle which is one of the core ethical foundational principles, outlined in the Belmont Report.

For more context, the need for IRBs to advance fairness and equitable distribution of risks and benefits for participants in clinical trials was cited in ASH’s Roadmap initiative published in Blood Advances, as a key barrier to enhancing access to trials. To address this barrier, the letter calls for AAHRPP to:

1. Develop Guidance to Promote the Attainment of Fair and Equitable Selection of Participants in Clinical Trials; and
2. Provide a Framework to Address Whether and When Payment Constitutes Coercion OR Undue Influence

ASK: Before this letter is shared with AAHRPP, ASH would appreciate your organization’s review and support. To that end, kindly review the detailed letter here and have the individual who can sign on your organization’s behalf complete this FORM no later than Friday, November 14th. Questions about this letter can be emailed to ASH’s Director of ASH Scientific Affairs, Alice Kuaban, MS, at [email protected]. Thank you for your consideration of this request! Best Regards,

Kelly Chavez Rose, PhD (She/her/ella) Chief Scientific Officer Main: 202.776.0544 | Mobile: 202.875.0502 Web: http://www.hematology.org | Email: [email protected] 2021 L Street NW #900, Washington, DC 20036

[Author]

Posts